H1B Salary Data

Home › Occupations › Chemists › South San Francisco, CA

Chemists in South San Francisco, CA: H-1B salaries

93 labor condition applications for this occupation with a work site in South San Francisco, CA. Median offered base salary $141,500; middle half $119,800–$152,186.

Applications (LCAs)93
Median offered salary$141,500
Middle half of salaries$119,800–$152,186
10th–90th percentile$93,600–$170,000

By wage level

Wage levelMedian salary
Level I (entry)$84,000
Level II (qualified)$104,499
Level III (experienced)$143,150
Level IV (fully competent)$148,117

The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.

Employers

EmployerLCAsMedian salary
Genentech, Inc.23$143,100
Amgen Inc.10$157,459
MRL San Francisco, LLC9$126,970
Cytokinetics, Inc.6$119,970
Abbvie Biotherapeutics Inc.6$145,000
Ideaya Biosciences Inc.4$148,060
R2M Pharma, Inc.4$126,970
Denali Therapeutics Inc.3$123,614
Eli Lilly and Company3$148,264
Apertor Pharmaceuticals Inc.2$162,500
Firefly Biologics, Inc.2$167,500
Insitro, Inc.2$141,558
Vilya, Inc.2$110,132
Circle Pharma, Inc.2$137,958
Alpha Consulting Corporation2$93,600
Mantra Bio, Inc.1$125,000
Mammoth Biosciences Inc.1$104,499
Sanofi US Services Inc.1$84,282
Thermo Fisher Scientific Inc.1$73,715
Frontier Medicines Corporation1$150,000
ORIC Pharmaceuticals, Inc.1$145,700
Nkarta, Inc.1$138,362
Lyterian Therapeutics1$280,800
Bayone Solutions, Inc.1$228,800
Terremoto Biosciences, Inc.1$160,888
Soley Therapeutics, Inc1$150,000
AbbVie Inc.1$146,000
Onepot AI, Inc.1$170,000

Job titles

H-1B sponsors in South San Francisco, CA →

Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).